BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 13, 2020
View Archived Issues
First patient enrolled in phase I study of GEM-103
Read More
FDA clears IND for ACE-1702 for the treatment of HER2-expressing solid tumors
Read More
Moderna begins phase II study of CMV vaccine mRNA-1647
Read More
Nomacopan achieves primary endpoint at interim analysis of phase III CAPSTONE study
Read More
Positive results from pivotal phase II study of loncastuximab tesirine in DLBCL
Read More
Novel ATX inhibitor shows promise as IOP-lowering therapy in vivo
Read More
Daiichi Sankyo presents a new orally potent analgesic, DS-54360155
Read More
Mutations in TTC29 gene linked to male infertility
Read More
Heptares Therapeutics describes new muscarinic acetylcholine M1 and/or M4 receptor agonists
Read More
New tankyrase 1/2 inhibitors patented by Forschungsverbund Berlin and collaborators
Read More
Curadev Pharma synthesizes new STING agonists
Read More
FGF21 switches sides in pancreatitis
Read More
Amyloid after amnesia?
Read More
Merck & Co. discovers PCSK9 inhibitors
Read More
Treatment effects may spread in LCA gene therapy
Read More
New NRTK1 inhibitors disclosed by Beijing Innocare Pharmaceutical Technology
Read More
Xuanzhu (Hainan) Biopharmaceutical identifies farnesoid X receptor agonists
Read More
Bio-Thera launches adalimumab biosimilar Qletli in China
Read More
AKCEA-TTR-LRx begins phase III cardiovascular outcomes study
Read More
ContraFect begins dosing in phase III study of exebacase for S. aureus bacteremia
Read More
Seelos reports interim phase I data on intranasal racemic ketamine
Read More
New REPAIR-MS phase II study begins with CNM-Au8 for MS
Read More